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ABSTRACT 
Heart failure (HF) is now considered an emerging epidemic of the 21
st
 century, affecting 5.7 
million Americans and causing a $32.7 million strain on the healthcare system. Most admitted 
HF patients enter the hospital through the ED; however, there are not comprehensive established 
guidelines and treatment goals for ED physicians. This retrospective chart abstraction study 
investigates the impact of ED treatment on HF patient outcomes to determine which treatment 
courses are most effective and efficient.  
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BACKGROUND 
WHAT IS HEART FAILURE? 
Heart failure (HF) is the inability of the heart to pump enough blood to meet the demands of the 
body.  This can manifest itself acutely or chronically, though most cases are chronic.  If the heart 
can no longer pump enough blood to the body, the body responds in an attempt to compensate.  
This compensation starts with the sympathoadrenal system, which (when stimulated) increases 
cardiac rate, contractility of the ventricles, and constriction of the arterioles.  This system also 
uses hormones and nerve signals to increase blood volume by increasing water reabsorption in 
the kidneys.  It accomplishes this by increasing renin secretion which activates the renin-
angiotensin-aldosterone system.  Activation of this system, in turn, leads to increased salt in 
water retained by the kidneys.  The increased volume gets backed up behind the heart, since its 
pumping function is impaired.   
Pumping inadequacy in the left ventricle leads to an increase in pressure in the left atrium.  This 
pressure backs up and causes the fluid to enter and congest the lungs (congestive heart failure, 
CHF).  If the pumping inadequacy is in the right ventricle, pressure builds in the right atrium and 
backs up into the rest of the body.  This causes edema in systemic circulation: swelling in the 
legs, ankles, and abdomen.  The increased blood volume also places additional stress on the heart 
through work overload.  The ventricles enlarge to compensate for the increased blood volume 
and have a higher metabolic demand for oxygen.  All of this leads to a cycle in which the heart’s 
inadequate pumping causes symptoms and systemic compensation which further aggravates the 
heart.  The heart’s inadequate pumping also leads to a reduced blood flow to the body.  This 
hypoperfusion can have effects (especially during physical activity), such as difficulty breathing, 
fatigue and dizziness.    
There are several different mechanisms of heart failure: systolic heart failure, diastolic heart 
failure, left heart failure, and right heart failure (Table 1).  These mechanisms are not mutually 
exclusive; patients may suffer from one or more of these types of heart failure. 
Table 1: Heart Failure Mechanisms. 
Heart Failure Type Mechanism Symptoms Causes 
Left Heart  
Failure 
left side, specifically the left 
ventricle has impaired function 
pulmonary edema, dyspnea, cough with 
pink-frothy mucus, decreased urine 
output, fatigue, weakness, weight gain 
MI, HTN, too much alcohol 
consumption, leaky heart valves, 
heart muscle infections 
Right Heart 
Failure 
right side, specifically the right 
ventricle, has impaired 
function 
edema and engorged veins in the lower 
extremities/hands, palpitations, 
weakness, fatigue, shortness of breath 
left ventricular failure, COPD, 
right ventricle infarction, 
pulmonary embolism 
Systolic Heart 
Failure 
one/both of the ventricles have 
impaired ejection upon 
contraction 
symptoms reflect those of left heart 
failure, right heart failure, or both 
causes reflect those of left heart 
failure, right heart failure, or both 
Diastolic Heart 
Failure 
refilling abnormality in 
one/both ventricles caused by 
ventricular stiffening 
symptoms reflect those of left heart 
failure, right heart failure, or both 
causes reflect those of left heart 
failure, right heart failure, or both 
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Heart failure patients that enter the emergency department (ED) are generally complaining of 
angina, edema, or dyspnea (Peacock and Emerman 2004; Bundkirchen and Schwinger 2004).  
They may also complain of persistent coughing and wheezing from the fluid buildup in the 
lungs.  The decreased blood flow can cause fatigue and lack of appetite/nausea as the body 
diverts towards more vital organs such as the brain and heart.  As the body compensates for this 
decreased blood blow, heart rate will increase and patients may complain of palpitations or a 
racing/throbbing heart.  Confusion or other altered mental status is also common, resulting from 
the ion and fluid imbalance.  
CHARACTERISTICS OF THE HF POPULATION 
Several studies have found a set of characteristics that typify the heart failure population.  In 
2005, the ADHERE database was created to define the characteristics and outcomes of admitted 
patients with a heart failure diagnosis (Adams et al. 2005).  This database was a multi-center 
project that enrolled 107,362 subjects.  The study recorded past medical history, treatment, 
diagnostic test results, vital signs, length of stay, and other outcomes to better characterize the 
heart failure population.  The findings are not a 100% accurate representation of the general 
population but do serve as a valid database to make some generalizations about the heart failure 
population as a whole.  This database found a mean ejection fraction (EF) of 34.4%, a median 
length of stay (LOS) of 4.3 days, required mechanical ventilation in 23% of patients, and an in 
hospital mortality rate of 4%.  This mortality rate increased to 10.6% for patients who required 
care in the intensive care unit (ICU).   
Other studies have found that heart failure patients commonly have a significant past medical 
history, including: hypertension (HTN), coronary artery disease (CAD), diabetes mellitus (DM), 
atrial fibrillation (A Fib), chronic obstructive pulmonary disease (COPD), and asthma (Adams 
2005; Gheorghiade et al. 2005).   A study in Worcester, MA in 2005 looked at mortality rates 
and factors affecting fatality risk in heart failure patients.  This study found an increased risk of 
fatality for older patients, patients with impaired renal function, patients arriving to the hospital 
with low blood pressure, patients with a history of anemia or stroke, and patients of normal/non-
obese weight (Goldberg).   Patients with high BUN, serum creatinine, and heart rate upon 
admission also had higher mortality rates (Goldberg 2005).   
STAGES OF HEART FAILURE (AHA) 
The American Heart Association (AHA) has published that there are four stages of heart failure.  
In the first stage (Stage A), patients show no symptoms or actual heart damage but are at high 
risk for developing heart failure.  This risk is based on a history of hypertension, diabetes, 
coronary artery disease, or family history of heart failure.  During this stage, preventative 
measures should be considered such as treatment for related diseases (HTN, DM, CAD), 
increased exercise, no smoking, and possible pharmacological interventions (ACE inhibitors, or 
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β blockers).  In Stage B, patients remain asymptomatic but now exhibit some heart dysfunction 
and should be managed pharmacologically.  In Stage C, symptoms arise, including: shortness of 
breath (SOB), fatigue, edema, reduced exercise tolerance.  Treatment for this stage includes ACE 
inhibitors, β blockers, diuretics, dietary management and other preventative strategies mentioned 
earlier.  In this stage, the therapies are successful in diminishing symptoms and treating heart 
failure.  The last stage (Stage D) is called refractory heart failure and is when, even with 
maximal therapy, patients experience worsening symptoms and poor quality of life with 
recurrent hospitalizations.  The therapy for this stage often includes palliative care or high tech 
procedures (i.e. transplants).   
PREVALENCE OF HEART FAILURE IN THE U.S. 
Heart failure is an emerging epidemic of the 21
st
 century in the United States (Massie 1997; 
Goldberg 2005). Recent studies estimate that 5.7 million Americans currently suffer from this 
disease, with an added 500,000 diagnosed every year (AHA 2009; Fonarow 2004).  The number 
of hospital discharges related to heart failure has been steadily increasing.  In 1979, 377,000 of 
the nation’s discharges were attributed to heart failure.  This number increased to 978,000 in 
1998 and 1,106,000 in 2006 (AHA 2009; AHA 2005; USDHHS 2004).  Over the decade of 
1985-1995, the number of hospitalizations with a heart failure diagnosis skyrocketed from 1.7 to 
2.6 million (AHA 2005; USDHHS 2004).  It has already become the leading cause of 
hospitalization for persons over the age of 65 and hospitalization numbers are expected to 
increase over the next two decades (Adams et al. 2005; Kannel 1994; Anonymous 1994).   
This drastic increase in prevalence of heart failure is partially a result of the aging baby boomer 
population (Massie 1997; Bundkirchen and Schwinger 2004; Goldberg 2005; Bonneux et al. 
1994).  In 2006 the 65 and older age group accounted for 12.1% of the population (Census 
Bureau 2006).  Current estimates predict that by 2020, that percentage will rise to 16.5% and by 
2050 it will rise to 20% (Census Bureau 2000).  Because heart failure is most prevalent in this 
elderly population, the aging baby boomers will cause a dramatic increase in the prevalence of 
heart failure.  Increases in heart failure diagnoses and incidences are also partially due to 
increased heart disease survival rates (Goldberg 2005).  Improved management and increased 
public awareness of myocardial infarction, diabetes, and hypertension have decreased early 
mortality rates from such diseases (O’Connell 2000).  With higher survival rates for these 
cardiac-related illnesses, the number of heart disease sufferers increases.  With more heart 
disease sufferers (a common cause of heart failure), there are more individuals with weakened 
hearts that contribute to the increased prevalence of heart failure.  
FINANCIAL BURDEN OF HEART FAILURE TREATMENT 
The treatment of this large, sick population is causing heart failure to become an increasing 
burden on the health care system, not only clinically, but also economically (Goldberg et al. 
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2005).  Although calculating the exact cost of heart failure management is difficult, some studies 
have ventured estimations.  O’Connell (2000) estimates that hospital charges average 
approximately $10,000 per heart failure visit.  The national expenditure for heart failure 
management is estimated to reach $32.7 billion annually (AHA 2009).  Approximately 50% of 
these expenses are accounted for by hospital stays (AHA 2004).  In recent years, Medicare has 
released statements that rank heart failure expenses as surpassing those of cancer (O’Connell & 
Bristow 1994; O’Connell 2000).   
MANAGEMENT OF HEART FAILURE IN THE EMERGENCY DEPARTMENT 
Approximately 75% of heart failure admissions enter the hospital through the emergency 
department (ED) (Silvers 2007).  Of all these HF admissions, 80% are diagnosed as such in the 
ED (Peakcock and Emerman 2004).  These statistics highlight the importance of the emergency 
department in the diagnosis and treatment of heart failure patients. 
DIAGNOSIS 
Diagnosis of heart failure is based on the signs and symptoms discussed earlier and clinical 
findings.  Clinical tests performed to diagnose heart failure include: B-type natriuretic peptide 
test, electrocardiogram, chest x-ray, and echocardiography (Hobbs 2004).   
The B-type natriuretic peptide (BNP) test is gaining popularity because it is a rapid, reliable 
biomarker that can be tested for from a patient’s blood (Peacock and Emerman 2004; Hobbs 
2004).  BNP is a neurohormone secreted by the ventricles when they are stretched (Morrian et al. 
2002).  Stretching is common in heart failure due to the increased blood volume and subsequent 
pressure overload.  When stretching occurs, BNP is secreted into the bloodstream, in a 
concentration dependent manner.  The peptide levels correlate to the severity of the heart failure 
incident and the patient’s prognosis (Morrian et al. 2002). For ED heart failure diagnoses, the 
BNP test accurately detects heart failure about 83% of the time and reduces diagnosis uncertainty 
from 43% to 11% (Morrian et al. 2002).  The test requires a small amount of the patient’s blood 
to be  
Table 2: BNP as a HF diagnostic tool. 
Blood BNP Concentration Heart Failure Severity Indication 
below 100 pg/mL no heart failure 
100-300 pg/mL heart failure is present 
300-600 pg/mL mild heart failure 
600-900 pg/mL moderate heart failure. 
above 900 pg/mL severe heart failure. 
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analyzed in a machine that determines the BNP concentration in the blood in pg/mL.  Normal 
BNP concentration is less than or equal to 100pg/mL; values above this indicate various levels of 
heart failure (Table 2).  Patients with severe decompensated heart failure can have blood BNP 
concentrations of up to 5000pg/mL. 
All patients suspected of having heart failure undergo at least one ECG while in the ED. This is a 
non-invasive method of detecting the heart’s electrical activity.  It is useful for determining the 
presence of arrhythmias, which are often present in heart failure patients, although no specific 
abnormal ECG feature indicates heart failure.  Heart failure patients also suffering from atrial 
fibrillation, atrial tachycardia, or ventricular tachycardia have a poorer prognosis than those not, 
so this information is an important part of ED diagnosis and care. (Shamsham and Mitchell) 
Chest radiography (chest x-ray) is a tool that aids in the diagnosis of many conditions affecting 
the contents of the chest.  It allows for the assessment of pulmonary congestion and for the 
differential diagnosis between heart failure and lung infection (such as pneumonia) (Nieminen 
2005).  Chest x-rays can help diagnose systolic vs. diastolic heart failure as well.  Hearts in 
systolic failure appear enlarged and have a larger cardiothoracic ratio.  Hearts in diastolic 
dysfunction do not show enlargement.  Chest x-rays of heart failure patients also show Kerley 
lines, lines that appear on the x-ray due to the fluid build-up associated with pulmonary edema 
(Figure 1 and Figure 2).  Haziness in the x-ray or pleural effusion are commonly associated with 
heart failure as well.  (Shamsham and Mitchell) 
  
  
Figure 1: Chest X-ray in Normal Patient. 
Picture copied from: http://www.med.yale.edu 
/intmed/cardio/imaging/findings/kerleylines/inde
x.html 
 
 
Figure 1: Chest X-ray in Heart Failure 
Patient.  Arrows indicate Kerley lines. Picture 
copied from: http://www.thics.com/cxrapps.jpg  
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Echocardiography is used to monitor ventricular function, valvular structure/function, pericardial 
pathology, and mechanical complications of a myocardial infarction (Nieminen 2005).  It is a 
sonogram (or ultrasound) of the heart that yields two-dimensional slice images of the heart.  
Using Doppler echocardiography, physicians can determine the flow rate of blood at any given 
point in the image.  This allows for the calculation of cardiac output and ejection fraction (EF).  
Ejection fraction is the percentage of blood that exits a ventricle during a single heart beat.  In a 
normal patient the ejection fraction is 50%, meaning that during contraction, 50% of the 
ventricle’s blood is pushed out (through the aorta or pulmonary arteries) and 50% remains as 
residual volume.  In heart failure patients, the EF is generally decreased since the heart cannot 
pump out as much volume.  However, heart failure patients may also have increased EFs caused 
by stiffening of the ventricle walls.   
 
During their stay in the ED, patients are monitored through other lab tests as a part of the 
diagnosis: partial pressure of O2 (pO2) for assessment of oxygenation, partial pressure of CO2 for 
assessment of respiratory adequacy, pH for assessment of acid/base balance.  Their vital signs 
and oxygen saturation (SpO2) are also monitored as a part of the diagnostic and treatment 
process.  
  
Figure 3: Echocardiogram for Normal 
Patient. (LV = Left Ventricle, RV = Right 
Ventricle, RA= Right Atrium) 
Figure 2: Echocardiogram in Heart 
Failure Patient Showing Enlarged Left 
Ventricle. (LV= Left Ventricle, RV= 
Right Ventricle, RA= Right Atrium) 
LV 
RV 
RA 
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TREATMENT 
There are a range of treatments for heart failure, each addressing different facets of the disease.  
Treatments include pharmacological interventions (such as morphine, vasodilators, ACE 
inhibitors, diuretics, β blockers, inotropes) and non-pharmacological interventions (such as 
oxygenation, mechanical ventilation).  In the ED, treatment generally aims to stabilize patients 
quickly through early administration of vasoactive medications and/or adequate 
ventilation/oxygen (Gheorghiade et al. 2005).   
The reduced blood flow of heart failure requires that patients be kept on supplemental oxygen to 
increase perfusion.  Patients that are breathing on their own and don’t require ventilation, may 
require oxygen supplied by a nasal cannula or non-rebreather mask at various oxygen flow rates.  
For these patients, low flow rates (2-6L/min) are generally sufficient for good oxygen saturation.  
Many patients, with more severe heart failure will require ventilation in the ED (or prior, during 
pre-hospital care).  Ventilation can be achieved through non-invasive (NIV) methods such as 
CPAP (continuous positive airway pressure) or BiPAP (bi-level positive airway pressure) which 
blow air at prescribed pressures into the patient’s airway to aid in respiration.  Invasive methods, 
such as endotracheal intubation, are used for more serious cases.  Patients who are in severe 
respiratory distress or who are not breathing at all will be intubated and ventilated mechanically.  
Non-invasive methods are generally the preferred method of ventilation, if adequate, because 
they reduce the need for intubation and mechanical ventilation (which are expensive and more 
harmful to the patient) (Nieminen 2005).   
Morphine has been used to treat heart failure in its early stages.  It induces venodilation, mild 
arterial dilation and reduces heart rate.  Because of these effects, it is used especially for restless, 
dyspneic patients (Nieminen et al. 2005).     
Diuretics help relieve the fluid congestion in heart failure patients through increasing urine 
output.  They induce excretion of water, Na
+
, Cl
-
, and other ions which has a number of effects 
on the body.  It decreases plasma volume, extracellular fluid volume, blood pressure and in turn, 
peripheral and pulmonary edema.  Diuretics have been the classic ED heart failure treatment 
since they can relieve one of the most pressing symptoms.  Most patients receive intravenous 
diuretic in the ED and as many as 3% receive it en route to the hospital (Peacock and Emerman 
2004).  However, some studies have linked diuretics with a decline in kidney function and worse 
overall outcomes (Gheorghiade 2005, Peacock and Emerman 2004).   Common diuretics are: 
furosemide (Lasix), bumetanide, and acetazolamide.   
About 30% of heart failure patients receive vasoactive therapy during their hospital stay 
(Peacock and Emerman 2004).  These types of therapy include inotropes and vasodilators and 
are usually given to patients with EFs less than 40, chronic renal insufficiency, and pulmonary 
edema.  Some research has found that these drugs can lead to side effects such as hypertension 
and increased mortality, without enough benefit to justify widespread use (Peacock and 
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Emerman 2004).  Because of this, their use is decreasing.  Vasoactive medications can be broken 
down into inotropes and vasodilators.  Vasodilators are the first line therapy for many heart 
failure patients as long as they have stable blood pressure and show signs of congestion and low 
dieresis.  Vasodilators increase the circumference of blood vessels (mostly veins, but arteries as 
well at higher dosages).  The common vasodilators are nitroglycerin, nitroprusside, isosorbide 
dinitrate and glyceryl trinitrate 5-mononitrate.  Natriuretics are the newest type of vasodilator.  
One of these medications, nesiritide, is a vasodilator that acts similarly to endogenous 
natriuretics.  It can cause vasodilation of veins, arteries, and coronary vessels which reduces 
stress on the heart and increases cardiac output without causing an increased oxygen demand by 
the heart muscle (as some medications do).  Vasodilators are only recommended for those with 
stable blood pressure because they greatly decrease blood pressure.  They can lead to severe 
drops in blood pressure which may exacerbate heart damage and renal hypoperfusion 
(Gheorghiade et al. 2005).  Inotropes are medications that affect muscle contraction strength.  
With heart failure, they are used to increase the heart’s pumping strength.  Although this has its 
benefits, it can increase the heart’s oxygen demand and cause heart damage and possibly 
increased mortality (Gheorghiade et al. 2005).  Common inotropes are: dopamine, dobutamine, 
and milrinone.  
Angiotensin converting enzyme (ACE)-inhibitors are used to treat heart failure as well, though 
there is much debate over which patients should receive and at what time during their hospital 
stay.  ACE inhibitors act on the vascular system by decreasing angiotensin II (AII) and 
aldosterone and increasing angiotensin I and plasma renin activity (Nieminen et al. 2005).  
Angiotensin II normally causes vasoconstriction, release of aldosterone, and release of 
vasopressin.  All of these events lead to an increase in blood pressure.  ACE inhibitors slow the 
activity of ACE, decreasing these processes and leading to a decrease in blood pressure.  With 
lower blood pressure, there is less stress on the heart and heart function can improve.  Some 
common ACE inhibitors are: enalapril (also known as vasotec/renitec) and lisinopril (also known 
as lisodur/lopril/novatec/prinivil/zestril.). 
 β-blockers are another class of therapy for heart failure patients.  Although heart failure had 
traditionally been a contraindication for β-blockers, studies in the 1990s found they can reduce 
risk of mortality and hospitalization in heart failure patients treated with normal heart failure 
medications.  It has recently become standard care for many heart failure patients (Chavey 2000).  
β blockers act by inhibiting the stimulation of β receptors.  This leads to a reduction in the effect 
of exertion on the heart, reduction in heart oxygen demand, decrease in heart rate, dilation of 
blood vessels, and increase in ejection fraction.  The most common β blockers are: metoprolol, 
bisoprolol, and carvedilol.    
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PROBLEMS ASSOCIATED WITH ED TREATMENT OF HEART FAILURE: 
THE ROLE OF THIS STUDY 
Despite its labeling as the new epidemic of the 21
st
 century, heart failure remains understudied in 
comparison with other cardiac diseases, such as acute coronary syndrome.  Gheorghiade et al. 
wrote in 2005: ―there is no consensus on its definition, epidemiology, pathophysiology, 
appropriate therapeutic options, and directions for future research.‖   
There has been controversy over what methods are most effective for treatment of heart failure. 
Debate over the effectiveness and safety of certain drugs has led to differences in treatment 
preferences among physicians.  While some guidelines advocate for early and aggressive diuretic 
use, other studies have found that higher/more frequent doses of diuretics can increase mortality 
rates or cause renal damage (Butler et al. 2004; Philbin, Cotto, and Rocco 1997; Gheorghiade, 
2005).  Similar controversies exist with administration and dosage guidelines for vasodilators.  
Studies continue to examine nitroglycerine, even after decades of use, to determine the most 
effective dosage.  Nesiritide, a newer vasodilator, has been supported in some studies for its 
symptom reduction and opposed in others for its cost and risk (Sackner-Bernstein et al. 2007; 
Peacock et al. 2006).  There are also no therapeutic goals for ED physicians to base their care on.  
With no goals in terms of vital signs or urine output, indecision about drug dosages and usage 
continues (Darling, personal communication).  To add to the indecision, 20% of heart failure 
patients are mis-diagnosed in the ER (Peacock and Emerman 2004).   
Because of this type of confusion and uncertainty, it has been recommended that more studies be 
completed to develop more effective care strategies (O’Connell 2000).  Prior to 2007, the only 
existing guidelines for heart failure treatment addressed general treatment and were not specific 
to care in the ED (Nieminen 2005; Hobbs 2004).  A set of guidelines for ED management of 
heart failure was released in 2007 by the American College of Emergency Physicians.  These 
guidelines filled a void by providing a standard of care for emergency physicians treating heart 
failure.  However, the guidelines were limited and addressed only four main issues: diagnosis 
with BNP, use of NIV, role of vasodilators, and the role of diuretics.  Even these four topics were 
labeled only as Level B (moderate clinical certainty) or Level C (limited supporting data) 
recommendations.   
Even with guidelines, there is little data about how actual ED management compares to the 
written standards.  In some cases, a treatment gap between what is recommended in guidelines 
and what ED physicians put into practice clinically has been discovered (Fonarow 2004).  For 
example, numerous studies have shown the benefit of ACE inhibitors and beta blockers 
(Hjalmarson, A. et al. 2000; CONSENSUS 1987; SOLVD 1991).  In these studies, both drug 
classes decreased mortality risk or re-hospitalization risk or both: ACE inhibitors reduced the all-
cause mortality rate by 20-25%, beta blockers reduced the mortality rate by 34-35% (Fonarow 
2004).  Since these studies were published, these drugs have been guidelines for all stabilized 
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patients with left ventricle systolic dysfunction (and no contraindications) (Fonarow 2004).  
Despite this, ACE inhibitors and beta blockers are underused in heart failure patients.   
In addition, little effort has been put into studying the effect of ED management of heart failure 
on patient outcomes.  Studies have shown that early re-admission for heart failure and mortality 
within 30 days of discharge are both independently associated with the care that patient received 
in the hospital (Fonarow 2004).  However, it is unknown whether ED care specifically effects 
patient outcomes or simply treats symptoms.  ED care in other diseases has been known to have 
significant impacts on patient outcomes.  Nguyen et al. (2000) observed the care of critically ill 
patients that entered the ED and later transferred to the ICU.  The results showed that ED care of 
critically ill patients greatly impacted the progression of organ failure and mortality and that 
predictable outcomes may be established prior to ICU admission (Nguyen 2000).  Another study 
in sepsis patients found similar results.  This study focused on Early Goal-Directed Therapy 
(EGDT) and its ability to improve survival in early care septic patients in the ED and ICU 
(Rivers et al. 2001).  This study enrolled some patients in EGDT (a method that changes the 
WAY traditional therapies are administered, not the type of therapy) and some in normal care 
and compared the outcomes.  They found that EGDT created patients with higher central venous 
oxygen saturation, lower lactate concentration, and higher blood pH than patients treated with 
traditional, long standing therapies (Rivers et al. 2001).  Patients treated with EGDT had higher 
survival rates as well.  Another study, from 1992 observed patient outcomes (mortality and 
hospital LOS) in patients that received pre-hospital medications heart failure medications vs. 
those who received no pre-hospital medications (Wuerz and Meador 1992).  The results showed 
that those treated pharmacologically in the pre-hospital setting received medications 
approximately 36 minutes earlier and had decreased mortality rates and hospital LOSs (Wuerz 
and Meador 1992).  These studies all support the idea that ED treatment timeliness and manner 
can have significant effects on patient outcomes.   
If ED care does affect outcomes in the case of heart failure, the HOW or WHAT remains 
unknown.  Beyond a lack of knowledge about how ED care affects short term patient outcomes 
in heart failure, there is also uncertainty about which measures are most important.  If ED heart 
failure management can in fact affect patient outcome, than should it focus on cardiopulmonary 
indices, symptom relief, hospital LOS, mortality, or some other outcome goal?  
Timing of diagnostic tests and treatment is another important part of emergency care.  A national 
study in 2007 (Diercks et al.) found that the longer patients spent in the ED, the further their care 
strayed from published guidelines.  Patients who spent 8 hours or more in the ED received 
inferior care and were less likely to meet treatment goals than patients who went 4 hours or less 
in the ED (Diercks et al. 2007).  Although the study didn’t address the reasons for the longer ED 
stays and their corresponding poor treatment, ED crowding is a likely suspect.  Crowding not 
only leads to longer ED stays but also overburdened EDs with higher patient to nurse ratios (2:1 
in the ICU, 10:1 in the ED) (Hollander and Pines 2007).  The ED is not set up for continuing care 
and reassessment; it is designed for stabilization, initial intervention, and discharge to allow for 
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prioritizing the next patient (Hollander and Pines 2007).  In addition to total time spent in the 
ED, for ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevated 
myocardial infarction (NSTEMI), several studies have found significant differences in outcomes 
based on timing of certain tests and therapies (Hollander and Pines 2007).  From these studies, 
early ECG administration, fibronolytic therapy, and balloon inflation for STEMI/catherization 
for NSTEMI have become well-known, accepted goals for patients with acute coronary 
syndrome (Braunwald et al. 2002; Hollander and Pines 2007).  It is not unreasonable to 
hypothesize that early care in heart failure might have similar effects.  Even in the case of 
STEMI/NSTEMI where it is accepted that early care is important, there are no guidelines with 
specific time periods for early treatment and reassessment (Hollander and Pines 2007).  Which 
time points are important for improved outcomes are also unknown: early diagnosis, early care, 
early reassessment, or early transfer to hospital floor.    For the above reasons, this study will 
also look at ED lengths of stay and the timing of medical care and whether this has effects on 
patients’ outcomes.   
Another issue is the heterogeneity of the heart failure population.  While most heart failure 
patients present to the ED with similar symptoms, the mechanisms (systolic vs. diastolic 
dysfunction) underlying their disease can vary greatly.  Recent studies have found that because 
of this, it is important to separate patients with systolic and diastolic dysfunction and treat them 
accordingly (Chavey 2000).  Because this information is recent, the idea of taking these 
underlying mechanisms into account in emergency care has not yet taken hold.  Women with 
heart failure tend to be older and have stiffened hearts with diastolic dysfunction.  They generally 
have normal to high EFs and have a history of hypertension and diabetes (Philbin et al 2000).  
Men with heart failure, on the other hand, tend to be younger and suffer from systolic 
dysfunction.  They generally have very low EFs and a poor prognosis.  The differences in the 
mechanism and prognosis of systolic and diastolic dysfunction, as well as the differences in heart 
failure between men and women are usually not addressed in ED care.  Outcomes may improve 
if these factors were taken into account in treatment during early care in the ED. 
In 2004, O’Connell wrote: ―resources and personnel are limited, efforts must be made to develop 
novel strategies to reduce the burgeoning cost of care of these [heart failure] patients without 
compromising effectiveness of that care.‖  More and more critically ill patients are being 
admitted to the ED as their first point of care due to increased patient volume, limited ICU space, 
and increased utilization of the ED as a source of primary care (Nguyen 2000).  In addition, 
nearly 75% of the hospital costs in a heart failure hospital admission are accumulated during the 
first 48 hours, which are directly affected by ED care (O’Connell 2000).  Because most hospitals 
lose money on heart failure admissions, strategies to decrease costs are valuable information 
(Peacock and Emerman 2004).  Thus, heart failure treatment presents a large economic and 
resource burden that requires new solutions.  The emergency department is a promising location 
for such new solutions since 80% of heart failure patients are admitted through the ED (Silvers 
2007).  Possible methods of decreasing costs include reducing hospital admissions from the ED, 
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decreasing hospital LOS, increasing use of the observation or clinical decision unit, reducing re-
admissions, and reducing the use of expensive, high-resource areas such as the ICU (Peacock 
and Emerman 2004).  All this must be done without affecting patient care.  Simply discharging 
patients earlier to decrease LOS can be detrimental to the patient and can be more costly if it 
leads to increased readmissions (O’Connell 2000).  O’Connell (2000) suggests that the focus 
should be on medical-based targets rather than economic-based targets such as stabilizing 
patients and improvement of primary, secondary, and tertiary care strategies (which will lead to 
decreased hospital admissions and decreased costs).  These medical-based targets may be a 
possibility in ED care to help decrease hospital costs. 
In addition to the obvious economic concerns, the high and increasing incidence of heart failure 
combined with its poor prognosis have caused it to reach epidemic status.  The risk of heart 
failure development in men and women over the age of 40 is approximately 1 in 5 (AHA 2009).  
For those diagnosed with heart failure, their 6 year mortality rate is between 77 and 84% 
(O’Connell 2000).  It may be possible that ED care has the potential to be more effective and 
efficient at treating heart failure patients.  This study will look at this possibility in the hopes of 
finding solutions that can lead to decreased mortality risk, shorter hospital stays, and less 
crowded EDs.   
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Figure 4: Accounting of Disclosures form added to the back of each chart 
used for the study. 
DATA COLLECTION 
Patients for this study were enrolled retrospectively from an existing ED heart failure database.  
Patients in this database were all discharged from UMass Memorial Medical Center between 
May and November of 2008 with a primary diagnosis of heart failure.  85 patients from this 
database were enrolled into this study.  These patients’ charts were pulled from medical records 
and information about their demographics and hospital stay were recorded on a data collection 
sheet (Figure 6).  This was an IRB approved study that did not require consent due to its non-
invasive, retrospective nature.  The following Accounting of Research Disclosures sheet (Figure 
5) was filed into each patient’s chart to indicate that their information was used in the study:  
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Figure 5: Data Collection Sheet used for the study. 
The following is the data collection sheet that was used, it indicates all information retrieved 
from each chart:   
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Figure 6: Example Portion of Excel Database. Names and Medical Record Numbers are blurred for 
patient privacy 
The demographics data were obtained from the chart and MEDITECH (an electronic database of 
UMass patient information).  This information includes: Name, MRN (Medical Record Number), 
Age, Gender.  Time and date of ED arrival/admission, admission location, and LOS were 
recorded as stated in MEDITECH Abstract, with LOS in whole days.  The tables of Pre-Hospital 
Medication, Vital Signs, Medication, Airway Management, Urine Output, and ER chart 
diagnosis were recorded from the physician and nurse ED records.  Home medications were 
recorded from the Medication Reconciliation Form.  Medical history was compiled from a 
combination of forms including the nurse records, physician records, discharge summary, and 
interdisciplinary care form.  Laboratory values (Na, Cl, K, HCO3, BUN, Cr, glucose, BNP) and 
EF were recorded from the Laboratory data section of MEDITECH. 
After all required data were collected, each data collection sheet was entered into an Excel 
database as seen in Figure 7.  A key for this database can be found in Table 3, which explains the 
definition of each column header.  
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Table 3: Information Entered into Excel Database (with definitions) 
Column Title Definition 
DOS Date of Stay (Admission Date) 
(Name) Patient Name (Last, First initial) 
Age Age (years) 
Gender Male or Female, where Male = 1, Female= 0 
n Patients number in the study 
MRN Medical Record Number 
LOS Length of Stay in whole days 
Floor Patient admission to a floor, where yes = 1, no = 0 
ICU Patient admission to the ICU, where yes = 1, no = 0 
Death Patient mortality/survival, where mortality = 1, survival = 0 
NIV Non-Invasive Ventilation (CPAP/BiPAP) during ED stay, where yes = 1, no = 0 
Vent/ETI Ventilation through Endotracheal Intubation, where yes = 1, no = 0 
Vaso? Administration of vasodilator during ED stay, where yes = 1, no = 0 
Min 1
st
 vasodil Minutes from ED arrival to administration of the first dose of vasodilator 
BP goal? Did the patient’s BP reach ≤ 140 systolic during the ED stay 
Min BP ≤ 140 Minutes from ED arrival to achievement of BP goal (≤ 140 systolic) 
Initial ED SBP ≤ 140 BP at goal (≤ 140 systolic) upon arrival to ED 
Diuretic Administration of diuretic during ED stay, where yes = 1, no = 0 
Min 1
st
 lasix Minutes from ED arrival to administration of the first dose of diuretic 
ACEI Administration of ACE-inhibitor during ED stay, where yes = 1, no = 0 
Min 1
st
 ACEI Minutes from ED arrival to administration of the first dose of ACE-inhibitor 
Total UO Total urine output during ED stay (in ml) 
BNP B-type natriuretic peptide value for any time during this hospital stay 
Creat Creatinine level for first set of labs 
ED arrival Time of ED arrival (in military time) 
To Floor Time of floor/ICU admission (in military time) 
Time to Admit Minutes between ―ED arrival‖ and ―To floor,‖ equal to total minutes in the ED 
3 week return? Patient return to ED for HF exacerbation in the next 21 days, where yes = 1, no = 0 
Blank (for other notes) 
Other notes such as: death during later admission, return outside the 21 day limit, 
admissions during the 21 day limit for other diagnoses, other important diagnoses 
during hospital stay 
 The data from the database was analyzed using the program GraphPad which contains statistics, 
curve fitting, scientific graphing abilities.   
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RESULTS & DISCUSSION 
CHARACTERISTICS OF STUDY POPULATION 
This study enrolled 85 patients, 50 males and 35 females.  The range of patient ages was 41-95 
years, with a mean age of 75.02 and standard deviation of ± 13.97. The average age for the 
female patients was 80 years and the average age for male patients was 69 years.  ED lengths of 
stay averaged at 587 minutes, or 9.78 hours, with a range of 40 to 1600 minutes.  Hospital 
lengths of stay ranged from 1 day to 22 days, with a mean of 5.23 days and a standard deviation 
of ± 4.3.  65 of the 85 patients were admitted only to a hospital floor after leaving the ED.  The 
average EF was 42%, the average BNP was 1468pg/mL, and the average urine output (UO) 
during ED stay was 1078mL.  A summary of this information can be found in Table 4.  Five 
patients were admitted only to the ICU after leaving the ED.  15 patients were admitted to both 
the ICU and a floor during their hospital stay.  Only three of the patients died during the studied 
admission.  44 patients arrived to the ED with systolic blood pressures at the goal (≤ 140mmHg), 
another 28 reached the blood pressure goal during their ED stay.  18 patients required non-
invasive ventilation, while three patients required intubation and invasive mechanical ventilation.  
Patient information regarding pharmacologic treatment can be found in Table 5.   
Table 4: Characteristics of Study Population during ED Stay 
Characteristic Minimum  Maximum Average 
Age  (years) 41 95 75.02 
ED LOS (minutes) 40 1600 587 
Hospital LOS (days) 1 22 5.23 
EF (% volume) 10 75 42 
BNP (pg/mL) 110 6125 1468 
UO (mL) 0 3055 1078 
Table 5: Drug Administration during ED Stay 
Treatment received Number of Patients Average time to Treatment (min) 
Vasodilator 34 40 
Diuretic 63 181 
ACE Inhibitor 3 389 
POPULATION VALIDATION 
There is a significant difference between EFs in men and women (p= 0.0292) and between EFs 
in young patients (<65 years) and old patients (>65 years) (p=0.0199).  These results (Figure 8 
and Figure 9) are consistent with existing data showing that the average EF for a female in the 
studied population was around 48% while the average EF for a male in the studied population 
was around 38% (Philbin et al 2000; Senni et al. 1998).  In addition, those above the age of 65 
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had an average EF of 45% while those under the age of 65 had an average EF of 33% (Philbin et 
al. 2000; Wong, Fukuyama, and Blanchette 1989).  As stated earlier, it is now believed that heart 
failure in men and women comes from distinct mechanisms.  In women, heart failure tends to 
occur later in life.  This is also consistent with our study population, in which the average female 
age was 80 years while the average male age was 69 years.  It usually manifests itself as diastolic 
dysfunction with a stiffened heart and normal to high EFs (Philbin et al 2000).  In men, heart 
failure tends to occur earlier in life, as a result of systolic dysfunction (Philbin et al. 2000).  Men 
generally have very low EFs and a poor prognosis.   This is thought to be due to gender-specific 
differences in myocardial adaptation to pressure overload.  A study of men and women with 
isolated systolic hypertension found differences in their echocardiographs (Krumholz, Larson, 
and Levy 1993).  Women tended to have concentric left ventricular hypertrophy with no changes 
in the inner ventricle size.  Men had eccentric hypertrophy with left ventricle chamber 
enlargement.  The fact that the data of this study is congruent with previously published data 
(Krumholz, Larson, and Levy 1993; Philbin and DiSalvo 1998; Philbin et al 2000) indicates that 
this study has targeted the correct population (heart failure patients).    
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ED LENGTH OF STAY 
Figure 10 shows that heart failure patients spend a significant amount of time in the ED, whether 
they are admitted to a hospital floor or the ICU.  There was an average ED stay of 430min (7.2 
hours) for those admitted to the ICU at some point during their stay and 630min (10.5hours) for 
those only admitted to a hospital floor.  This supports the hypothesis that the ED does have an 
effect on patient care since they spend a large amount of time in the ED for each heart failure 
admission.  As mentioned earlier, recent national large-scale studies have found that ED length 
of stay can have large impacts on patient outcomes (Diercks et al 2007).  As ED and hospital 
crowding becomes an increasingly common problem, critically ill patients spend longer in the 
ED as they await transfer.  With the ED not intended to provide on-going care and reassessment, 
these patients often suffer from a lack of attention and care that could improved with shorter ED 
stays.  It should be noted that this issue is not solely an ED problem.  Part of the cause of ED 
crowding and prolonged ED stays are total hospital crowding; patients waiting in the ED for 
available beds on a hospital floor.  A larger sample size and investigation into the causes of such 
stays area few of the next steps for this research.     
  
Figure 7: Average Ejection Fraction in Males 
and Females. There was a statistically significant 
difference between these two populations, 
p=0.0292, run as a two-tailed Student’s T test. 
Figure 8:  Average Ejection Fraction in Younger 
Patients and Older Patients.  There was a 
statistically significant difference between these two 
populations, p = 0.0199, run as a two-tailed Student’s 
T test. 
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EARLY DIURETIC ADMINISTRATION 
Figure 11 shows the effect of early diuretic administration on patient length of stay.  This 
comparison yielded p=0.330 with a one-tailed Student’s T test (hypothesis: early use of diuretics 
in the ED for patients with heart failure will lead to a decreased length of stay).  The results 
found that the length of stay was 0.29 days  (6.96 hours) longer for patients who did not receive 
diuretic early in their ED stay.  Diuretics are administered to most heart failure patients during 
Figure 9: Time Spent in the ED.  
The time spent in the ED between 
ED admission and transfer to a floor 
or ICU. (p=0.0167, run as a two-
tailed Student’s T test) 
Figure 10:  Length of Stay and 
Timing of Diuretic Administration.  
Difference not statistically different, 
p=0.330, run as a one-tailed Student’s T 
test. 
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their hospital stay.  Although certain aspects of diuretic administration have been analyzed, 
timing of administration remains understudied.  This study compared the outcomes in patients 
that received diuretic earlier in their ED stay (<120min after ED arrival) or later in their ED stay 
(>120min after ED arrival).  Although there is a slight decrease in LOS for patients who received 
early diuretic, there is currently no statistical difference.  However, the somewhat low p value 
(p=0.330) indicates that there might be statistical significance for this comparison in a larger 
population size.  If the difference between the two groups remained the same with the addition of 
another 500-600 patients in each group, the results would likely become significant.  Large 
sample sizes can find significance in very small differences where this small sample size cannot.  
Small differences in hospital stay can have large impacts on patients and hospitals.  For hospitals 
it frees up beds for additional patients and reduces cost for each patient.  With the high volume 
of heart failure patients, small differences can add up to big savings.  For patients, less time in 
the hospital may have positive impacts on their physical and emotional well-being.   
The limitations of studies that involve length of stay should be noted.  Because of the many 
confounding variables, length of stay is a hard outcome to analyze.  First, length of stay (as used 
in this study) is based on the number of calendar days that a patient’s stay spans, not their total 
hours divided by 24 hours/day.  Therefore, the length of stay can be somewhat inaccurate.  
Second, patient length of stay is affected by many other variables.  Patient discharge can be 
determined by ambulance or family availability for pick up, meal times, infection or other illness 
acquired after the hospital admission, etc.  This means that length of stay is not simply a function 
of patient health.  Hopefully larger sample size would help to eliminate the effect of some of 
these variables.  Continuing research in this area should also attempt to exclude patients whose 
length of stay is definitely affected by these variables.   
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CONCLUSIONS: LIMITATIONS AND AREAS FOR FUTURE RESEARCH 
Despite its labeling as the new epidemic of the 21
st
 century, heart failure remains understudied.  
This has led to a lack of understanding of how heart failure occurs, what treatments are most 
effective, and which patient outcomes are most important. Because of this type of confusion and 
uncertainty, it has been recommended that more studies be completed to develop more effective 
care strategies (O’Connell 2000).  This study attempted to answer some of the questions about 
heart failure treatment in the ED.  Future studies can build off of these methods and improve 
them with increased patient enrollment, expanded investigation, and tightened control of 
confounding variables. 
Possibly the most obvious flaw in this research was the small population size of 85 patients.  
This research needs to be expanded to enroll many more patients. To find significance in very 
small differences between groups, this study would need to enroll at least 1,200 more patients.  
Other heart failure studies such as the ADHERE study have enrolled upwards of 100,000 
patients.  Making this study a large-scale, multi-center study could improve its accuracy and 
representativeness of the nation’s heart failure population as a whole.   
Future research in this area might expand the research and look into different variables of 
emergency care as well. For example, although this study looks at how long patients spend in the 
ED waiting for transfer to a hospital floor, it does not take into account the length of their pre-
hospital ride or the length of their symptoms prior to hospitalization.  These might be variables to 
look into, either to study specifically, or to control in order to diminish their effect on the results.   
Future studies could also analyze the ED treatment methods more intensely.  For many of the 
current treatment options, timing, dosage, and dosage frequency remain debated issues (Butler et 
al. 2004; Philbin, Cotto, Rocco 1997; Gheorghiade, 2005; Sackner-Bernstein et al. 2007; 
Peacock et al. 2006).  Drug administration time was investigated to determine time sensitivity, 
however drug dosage was not.  Perhaps giving larger or smaller dosages of some medications 
could have an effect on short term outcomes.  Similarly, the frequency of such doses could also 
have an effect on patient outcome.  The collective affect of timing, dosage, and dosage frequency 
could be studied together in future research as well, to see how the three factors are inter-related.  
The use of supplemental oxygen, non-invasive ventilation, and endotracheal intubation are other 
factors that were recorded during this study but could be investigated more deeply. 
One issue with this study was poor documentation in the ED notes.  Treatment, vital signs, urine 
output, and ED diagnoses were sometimes illegible or undocumented.  This can yield results that 
are not truly representative of the study population.  This was especially true for urine output 
records.  For many patients there was no recorded urine output, despite ED stays surpassing 8 
hours and administration of diuretics.  This is likely the result of poor documentation, rather than 
a lack of urination.  Future studies should keep the impact of poor documentation in mind and try 
to minimize its effect, possibly through exclusion of patients with incomplete documentation or 
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through prospective studies that monitor patient care in real time.  It might also be of interest to 
perform a study that looks at the effects of poor documentation on patient care in the ED.   
Considering the effects of ED and hospital crowding discussed earlier, future studies might 
consider its effects on care of heart failure patients.  Crowding leads to a decreased nurse to 
patient ratio and can decrease quality of care.  Another step, in the future, might be to look at 
how crowding effects heart failure patient outcomes.  Do patients treated in the ED hallway have 
poorer outcomes than those that receive immediate care in an ED room?  Do patients that wait 
for a hospital room in ―ED inpatient waiting‖ experience poorer results?  Do patients treated in 
overburdened EDs suffer the consequences of a lack of attention?  These issues could be 
investigated as additional variables affecting short term outcomes such as length of stay or 
readmission.   
Patient initial condition was a problem encountered during data analysis.  Patients receive 
different treatment courses depending on how they present to the ED.  By the laws of triage, it is 
often the case that the sickest patients receive more attention and earlier treatment.  This could 
lead to a correlation of early drug administration with poor outcome simply because those 
patients that receive the drug early are worse off to begin with.  In the same sense, the research 
might find that patients that receive ventilation (invasive or non-invasive) tend to have worse 
outcomes.  Again, these patients are usually sicker upon arrival, and therefore have poorer 
outcomes.  In the future, controlling for patient condition could be helpful to minimize this 
problem.  Using a standardized system to determine a patient’s condition at various times 
throughout their stay could control for this.  A scale like the APACHE II score (which uses a 71 
point scale to calculate a severity of disease score based on 12 physiologic measurements) 
calculated for ED arrival, hospital admission and discharge is one way to accomplish this.  With 
this score, patients could then be compared to themselves or analyzed as groups of patients with 
similar disease severity.  In addition to further controlling confounding variables, this adds an 
interesting dimension to the research.  Researchers could investigate whether certain aspects of 
ED care affect patients with varying disease severities differently. 
Lastly, in addition to changing some study aspects and controlling for confounding variables, 
future research could look at other outcomes as well.  This study focused on short term 
outcomes, yet long term outcomes may be just as, or even more important.  Patient readmission 
or death over long post-discharge periods (such as over the following few months or years)  may 
be other important outcomes to investigate.   Other outcomes to consider include: ejection 
fraction, stable blood pressure, reduced edema/congestion.  
The hope of this study is that it will serve as an initial investigation into ED care of heart failure.  
This study has significant flaws yet can serve as a step towards a greater understanding of ED 
heart failure treatment.  It highlights some successful and unsuccessful clinical research methods 
while underscoring the need for further study in the area of ED management of heart failure.    
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